Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Completed · Phase 2
Conditions studied: Hepatitis C, Cirrhosis, Portal Hypertension, With or Without Liver Decompensation
In brief
This study will evaluate the antiviral efficacy of combination therapy with sofosbuvir (SOF) plus ribavirin (RBV) for 48 weeks in adults with compensated and decompensated chronic hepatitis C virus (HCV) infection. Approximately 50 adults will be randomized (1:1) to receive study drug for 48 weeks or take part in an untreated observational arm for the first 24 weeks followed by study drug for another 48 weeks.
Key facts
- Study ID
- NCT01687257
- Run by
- Gilead Sciences
- People needed
- 50
- Starts
- 2012-07-01
- Expected to finish
- 2015-10-01
- Last updated by the study team
- 2016-09-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Chronic infection with Hepatitis C with HCV RNA > 1000 IU/mL
- Individuals with cirrhosis with Child-Pugh score < 10
- Esophageal or gastric varices on endoscopy within 6 months prior to or at screening
- Hepatic Venous Pressure Gradient (HVPG) > 6 mmHg
- Body mass index (BMI) ≥ 18 kg/m\^2
- Naïve to all nucleotides/nucleoside treatments for chronic HCV infection
You may not qualify if…
- Have any serious or active medical or psychiatric illness which, in the opinion of the investigator, would interfere with subject treatment, assessment, or compliance
- HIV or chronic hepatitis B virus (HBV) infection (HBsAg positive)
- Alpha-fetoprotein (AFP) > 50 unless negative imaging for hepatic masses within the last 6 months or during screening
- Refractory ascites as defined by requiring paracentesis > twice within 1 month prior to screening
- Active variceal bleeding within 6 months of screening
- Expected survival of < 1 year
- History of hepatorenal, or hepatopulmonary syndrome.
- Evidence of renal impairment (CrCl < 50 mL/min)
- History of major organ transplantation, including liver transplant.
Where it is running
- Study site — Aurora, Colorado, United States
- Study site — Boston, Massachusetts, United States
- Study site — Rochester, Minnesota, United States
- Study site — Philadelphia, Pennsylvania, United States
- Study site — Newtown, New South Wales, Australia
- Study site — Leclerc, Clichy, France
- Study site — Grafton, Auckland, New Zealand
- Study site — Barcelona, Barcelona, Spain
- Study site — Majadahonda, Madrid, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.